Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Interactions Between Pharmaceutical Companies and Patient Advocacy Groups in Japan: A Qualitative and Quantitative Interview Study.

PMID: 41332486 · 2025

JournalRisk management and healthcare policy
Year2025
PMID41332486

Abstract

In Japan, the financial relationship between pharmaceutical companies and patient advocacy groups is considered to be weak; however, limited studies have examined this relationship. The financial relationship and issues surrounding the relationship between the two parties remain unclear. This study investigated the relationship between Japanese patient support groups and pharmaceutical companies by interviewing 10 pharmaceutical companies and examining the underlying challenges. Conducted from 2

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.